Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Turoctocog alfa pegol (N8-GP) in Chinese patients with haemophilia A
NCT05082116Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of turoctocog alfa pegol in hemophilia A, sponsored by Novo Nordisk. Started Sep 2021; status: completed.
02
Drugs
turoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05082116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05082116.